These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19939703)

  • 1. Adjuvant activity mediated by iNKT cells.
    Fujii S; Motohashi S; Shimizu K; Nakayama T; Yoshiga Y; Taniguchi M
    Semin Immunol; 2010 Apr; 22(2):97-102. PubMed ID: 19939703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy.
    Taniguchi M; Tashiro T; Dashtsoodol N; Hongo N; Watarai H
    Int Immunol; 2010 Jan; 22(1):1-6. PubMed ID: 19858073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
    Motohashi S; Okamoto Y; Yoshino I; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy.
    Okita K; Motohashi S; Shinnakasu R; Nagato K; Yamasaki K; Sato Y; Kitamura H; Hijikata A; Yamashita M; Shimizu K; Fujii S; Ohara O; Taniguchi M; Sakaida I; Nakayama T
    Cancer Sci; 2010 Nov; 101(11):2333-40. PubMed ID: 20804502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant natural killer T cell-based immunotherapy for cancer.
    Motohashi S; Nakayama T
    Immunotherapy; 2009 Jan; 1(1):73-82. PubMed ID: 20635975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
    Paget C; Bialecki E; Fontaine J; Vendeville C; Mallevaey T; Faveeuw C; Trottein F
    J Immunol; 2009 Feb; 182(4):1846-53. PubMed ID: 19201836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells.
    Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
    Clin Immunol; 2008 Oct; 129(1):145-54. PubMed ID: 18707922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
    Gabriel L; Morley BJ; Rogers NJ
    Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.
    Pulaski BA; Smyth MJ; Ostrand-Rosenberg S
    Cancer Res; 2002 Aug; 62(15):4406-12. PubMed ID: 12154047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.
    Faveeuw C; Trottein F
    Cancer Res; 2014 Mar; 74(6):1632-8. PubMed ID: 24599135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells.
    Uemura Y; Liu TY; Narita Y; Suzuki M; Nakatsuka R; Araki T; Matsumoto M; Iwai LK; Hirosawa N; Matsuoka Y; Murakami M; Kimura T; Hase M; Kohno H; Sasaki Y; Ichihara Y; Ishihara O; Kikuchi H; Sakamoto Y; Jiao SC; Senju S; Sonoda Y
    J Immunol; 2009 Jul; 183(1):201-8. PubMed ID: 19542431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
    Exley MA; Friedlander P; Alatrakchi N; Vriend L; Yue S; Sasada T; Zeng W; Mizukami Y; Clark J; Nemer D; LeClair K; Canning C; Daley H; Dranoff G; Giobbie-Hurder A; Hodi FS; Ritz J; Balk SP
    Clin Cancer Res; 2017 Jul; 23(14):3510-3519. PubMed ID: 28193627
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo activation of invariant V alpha 14 natural killer T cells by alpha-galactosylceramide sequentially induces Fas-dependent and -independent cytotoxicity.
    Lisbonne M; Hachem P; Tonanny MB; Fourneau JM; Sidobre S; Kronenberg M; Van Endert P; Dy M; Schneider E; Leite-de-Moraes MC
    Eur J Immunol; 2004 May; 34(5):1381-8. PubMed ID: 15114671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.